CR20220604A - Anticuerpos biespecíficos para linfocitos t activados por proteasa - Google Patents

Anticuerpos biespecíficos para linfocitos t activados por proteasa

Info

Publication number
CR20220604A
CR20220604A CR20220604A CR20220604A CR20220604A CR 20220604 A CR20220604 A CR 20220604A CR 20220604 A CR20220604 A CR 20220604A CR 20220604 A CR20220604 A CR 20220604A CR 20220604 A CR20220604 A CR 20220604A
Authority
CR
Costa Rica
Prior art keywords
protease
idiotype
activatable
cell activating
bispecific molecules
Prior art date
Application number
CR20220604A
Other languages
English (en)
Inventor
Martina Geiger
Gutierrez Cirlos Alejandro Carpy
Christian Klein
Ekkehard Moessner
Thomas Hofer
Anne Freimoser-Grundschober
Peter Bruenker
Christiane Neumann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220604A publication Critical patent/CR20220604A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere en general a nuevas moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo. La presente invención también se refiere a polinucleótidos que codifican dichas moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo, y vectores y células huésped que comprenden dichos polinucleótidos. La invención se refiere además a procedimientos para producir las moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo de la invención, y a procedimientos de uso de estas moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo en el tratamiento de una enfermedad
CR20220604A 2020-06-19 2021-06-17 Anticuerpos biespecíficos para linfocitos t activados por proteasa CR20220604A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181072 2020-06-19
PCT/EP2021/066335 WO2021255137A1 (en) 2020-06-19 2021-06-17 Protease-activated t cell bispecific antibodies

Publications (1)

Publication Number Publication Date
CR20220604A true CR20220604A (es) 2023-01-23

Family

ID=71111324

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220604A CR20220604A (es) 2020-06-19 2021-06-17 Anticuerpos biespecíficos para linfocitos t activados por proteasa

Country Status (18)

Country Link
US (1) US20230287145A1 (es)
EP (1) EP4168444A1 (es)
JP (1) JP7815150B2 (es)
KR (1) KR20230025667A (es)
CN (1) CN115698080A (es)
AR (1) AR122659A1 (es)
AU (1) AU2021291002A1 (es)
BR (1) BR112022024469A2 (es)
CA (1) CA3177239A1 (es)
CL (1) CL2022003522A1 (es)
CO (1) CO2022017261A2 (es)
CR (1) CR20220604A (es)
IL (1) IL296429A (es)
MX (1) MX2022015890A (es)
PE (1) PE20231552A1 (es)
PH (1) PH12022500026A1 (es)
TW (1) TW202214704A (es)
WO (1) WO2021255137A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128876A1 (es) * 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
WO2024040127A2 (en) * 2022-08-16 2024-02-22 Northwestern University Anti-tyrp1 bi-specific t cell engaging protein for treatment of tyrp1-expressing melanoma
EP4594353A1 (en) * 2022-09-28 2025-08-06 F. Hoffmann-La Roche AG Improved protease-activatable t cell bispecific antibodies
EP4761818A1 (en) * 2023-08-18 2026-06-24 F. Hoffmann-La Roche AG Protease activatable fc domain binding molecules
CN122422352A (zh) * 2023-12-11 2026-07-17 豪夫迈·罗氏有限公司 蛋白酶可活化的Fc结构域结合分子

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808353C2 (de) 1977-04-18 1984-01-19 Hitachi Metals, Ltd., Tokyo Ohrring
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
EP4015533A1 (en) 2015-10-29 2022-06-22 F. Hoffmann-La Roche AG Anti-variant fc-region antibodies and methods of use
JP7015244B2 (ja) * 2016-03-22 2022-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ｔ細胞二重特異性分子
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
WO2018108759A1 (en) * 2016-12-13 2018-06-21 F. Hoffmann-La Roche Ag Method to determine the presence of a target antigen in a tumor sample
SG11202102859TA (en) * 2018-12-21 2021-04-29 Hoffmann La Roche Antibodies binding to cd3

Also Published As

Publication number Publication date
WO2021255137A1 (en) 2021-12-23
BR112022024469A2 (pt) 2023-01-17
CO2022017261A2 (es) 2023-02-27
CA3177239A1 (en) 2021-12-23
JP7815150B2 (ja) 2026-02-17
MX2022015890A (es) 2023-01-24
PH12022500026A1 (en) 2024-05-06
KR20230025667A (ko) 2023-02-22
EP4168444A1 (en) 2023-04-26
PE20231552A1 (es) 2023-10-03
TW202214704A (zh) 2022-04-16
AU2021291002A1 (en) 2022-10-13
CN115698080A (zh) 2023-02-03
AR122659A1 (es) 2022-09-28
US20230287145A1 (en) 2023-09-14
IL296429A (en) 2022-11-01
CL2022003522A1 (es) 2023-07-21
JP2023529982A (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
MX2018011542A (es) Moleculas biespecificas de celulas t activadas por proteasas.
PH12022500026A1 (en) Protease-activated t cell bispecific antibodies
AR120543A2 (es) Moléculas biespecíficas de células t activadas por proteasas
MX2020007012A (es) Anticuerpos de union a gprc5d.
EA202192103A1 (ru) Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
JOP20230192A1 (ar) جسم مضاد ثلاثي النوعية يستهدف bcma، وgprc5d، وcd3
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
PH12022500024A1 (en) Immune activating fc domain binding molecules
PH12018500634A1 (en) Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
AR041650A1 (es) Anticuerpos que se unen a polipeptidos ca125/o772p cuando estos se encuentran asociados a las celulas. metodos relacionados
MX2024003355A (es) Anticuerpos anti-cd3.
EA201892774A1 (ru) Антитела
EA201500876A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
AR106365A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112019008634A2 (pt) anticorpos anti-pd-l1 e variantes
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
EA201891966A1 (ru) Молекулы, связывающие bcma, и способы их применения
NO20075635L (no) Antigenbindende molekyler som har modifiserte Fc-regioner og endret binding til Fc-reseptorer
EA201890169A1 (ru) Тау-связывающие антитела
CR10082A (es) Anticuerpos dirigidos a her-3 y usos de los mismos
BR112019005129A2 (pt) anticorpos anti-pd-1
EA201490693A1 (ru) Выделенное антитело или его антигенсвязывающий фрагмент (варианты), выделенный полинуклеотид (варианты), выделенный полипептид (варианты), клетка-хозяин, композиция (варианты) и способ лечения заболеваний или нарушений цнс животного организма (варианты)
EA201400254A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки